Abstract: The present invention relates to indoline-based compounds that inhibit Rho-associated protein kinase (ROCK) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of inhibiting ROCK activity and methods for treating, for example cerebral cavernous malformation syndrome (CCM) and cardiovascular diseases using the compounds and pharmaceutical compositions of the present invention.
Type:
Grant
Filed:
December 29, 2021
Date of Patent:
February 27, 2024
Assignee:
Cervello Therapeutics, LLC.
Inventors:
Matthew Randolph Lee, Anthony Joseph Varano, Jr., Thomas P. Bobinski
Abstract: The present invention relates to indoline-based compounds that inhibit Rho-associated protein kinase (ROCK) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of inhibiting ROCK activity and methods for treating, for example cerebral cavernous malformation syndrome (CCM) and cardiovascular diseases using the compounds and pharmaceutical compositions of the present invention.
Type:
Grant
Filed:
May 5, 2020
Date of Patent:
February 15, 2022
Assignee:
Cervello Therapeutics, LLC.
Inventors:
Matthew Randolph Lee, Anthony Joseph Varano, Jr., Thomas P. Bobinski
Abstract: The present invention relates to indoline-based compounds that inhibit Rho-associated protein kinase (ROCK) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of inhibiting ROCK activity and methods for treating, for example cerebral cavernous malformation syndrome (CCM) and cardiovascular diseases using the compounds and pharmaceutical compositions of the present invention.
Type:
Grant
Filed:
November 6, 2019
Date of Patent:
August 18, 2020
Assignee:
Cervello Therapeutics, LLC.
Inventors:
Matthew Randolph Lee, Anthony Joseph Varano, Jr.